Efficacy of AVT04, a Biosimilar to Ustekinumab, in Managing Plaque Psoriasis: Findings from a 28-Week Real-World Study - Takeaways - MDSpire

Efficacy of AVT04, a Biosimilar to Ustekinumab, in Managing Plaque Psoriasis: Findings from a 28-Week Real-World Study

  • By

  • Edoardo Mortato

  • Marina Talamonti

  • Lorenzo Savastano

  • Lorenzo Marcelli

  • Lorenzo Tofani

  • Valerio Gneo

  • Domenico Marrapodi

  • Maria Rosa Ingrosso

  • Luca Bianchi

  • Marco Galluzzo

  • March 13, 2026

  • 0 min

Share

  • 1

    AVT04, a biosimilar to ustekinumab, demonstrated sustained clinical efficacy in managing plaque psoriasis over a 28-week study.

  • 2

    Complete remission was achieved in 54.5% of ustekinumab-naïve patients treated with AVT04.

  • 3

    Switching from reference ustekinumab to AVT04 was found to be effective and safe for ustekinumab-switched patients.

  • 4

    The adoption of AVT04 is cost-saving for the Italian National Health Service, enhancing access to biologic therapies.

  • 5

    The study supports the efficacy and safety of AVT04 in diverse real-world patient scenarios, including bio-naïve and bio-experienced groups.

Original Source(s)

Efficacy of AVT04, a Biosimilar to Ustekinumab, in Managing Plaque Psoriasis: Findings from a 28-Week Real-World Study

  • by Edoardo Mortato, Marina Talamonti, Lorenzo Savastano, Lorenzo Marcelli, Lorenzo Tofani, Valerio Gneo, Domenico Marrapodi, Maria Rosa Ingrosso, Luca Bianchi, Marco Galluzzo

  • March 13, 2026

Related Content

Guselkumab Shows Psoriasis Benefit in Darker Skin Tones

Randomized trial suggests sustained clearance across darker skin tones.

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

Envudeucitinib: A Next-Generation Allosteric TYK2 Inhibitor - A Comprehensive Review